Under the terms of the agreement, Novozymes Biopharma will exclusively supply its recombinant human albumin, Recombumin, for the continued development and commercialization of ConjuChem’s PC-DAC:Exendin-4.
The agreement calls for the initiation of additional capacity expansion of Novozymes Biopharma’s Nottingham, England facility as well as additional expansion as global demand for PC-DAC:Exendin-4 increases. The agreement also allows ConjuChem to fully assign all rights to a PC-DAC:Exendin-4 licensee.
In a separate agreement, ConjuChem and Novozymes Biopharma entered into a pipeline product agreement by which Novozymes Biopharma will also supply Recombumin or other recombinant albumin products for the further development of ConjuChem’s R&D product candidates.
Mark Perrin, president and CEO of ConjuChem, said: “Recombumin is an important part of our current technology and Novozymes Biopharma has been an integral partner in the development of our peptide conjugation platform. These two agreements further solidify our relationship and are validation of the promise of our technology.”